Response to checkpoint inhibition in non-small cell lung cancer with molecular driver alterations

…, A Tufman, K Kahnert, BA Bollmann… - Oncology research and …, 2020 - karger.com
Aims: Non-small cell lung cancer (NSCLC) patients with EGFR mutations do not respond
well to checkpoint inhibitors. However, little is known about the activity of immunotherapy in …

[HTML][HTML] Design and rationale of the HANSE study: a holistic German lung cancer screening trial using low-dose computed tomography

…, F Lasch, BA Bollmann… - RöFo-Fortschritte auf …, 2022 - thieme-connect.com
Despite the high prevalence and mortality of lung cancer and proven effectiveness of low-dose
computed tomography (LDCT) to reduce mortality, Germany still lacks a national …

Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor‐associated neurotoxicity

…, G Körner, T Seeliger, G Beutel, BA Bollmann… - Cancer …, 2023 - Wiley Online Library
Background Oncological patients can benefit substantially from treatment with immune
checkpoint inhibitors (ICI). However, there is a growing awareness of immune‐related adverse …

Cellular analysis in bronchoalveolar lavage: inherent limitations of current standard procedure

BA Bollmann, B Seeliger, N Drick… - European …, 2017 - Eur Respiratory Soc
Bronchoalveolar lavage (BAL) is an established procedure for diagnosing respiratory
infections and characterising non-infective lung diseases [1]. Increasingly, emphasis has been …

[HTML][HTML] A Case Report and Review of the Literature: Infectious Aneurysm Formation in the Pulmonary Arteries—A Rare but Perilous Sequela of Persisting Infection …

…, B Fischer, L Häbel, F Laenger, BA Bollmann - Frontiers in …, 2022 - frontiersin.org
Septic aneurysms of the pulmonary artery are rare conditions, with few cases having been
reported worldwide. They are assumed to result from septic emboli that cause a local …

Response to checkpoint inhibition in lung cancer with molecular driver alterations.

…, K Kahnert, D Kauffmann-Guerrero, BA Bollmann… - 2018 - ascopubs.org
e21071 Background: Checkpoint inhibitors are widely used in NSCLC. While there is evidence
that EGFR mutation driven tumours respond poorly to checkpoint inhibition, little is known …

Enoximone in status asthmaticus

O Schulz, O Wiesner, T Welte, BA Bollmann… - ERJ open …, 2020 - Eur Respiratory Soc
Bronchial asthma is a chronic disease affecting >300 million people worldwide [1]. The most
severe disease manifestation is status asthmaticus, which can be unresponsive to medical …

Pulmonary Artery Aneurysm in Longstanding Idiopathic Pulmonary Arterial Hypertension

CA Hinze, DH Park, BA Bollmann - Deutsches Ärzteblatt …, 2023 - ncbi.nlm.nih.gov
… med., 1 and Benjamin-Alexander Bollmann, Dr. med. …

Necrotizing Sarcoid Granulomatosis (NSG)

…, J Vogel-Claussen, BA Bollmann - Deutsches Ärzteblatt …, 2023 - ncbi.nlm.nih.gov
… Dr., ** and Benjamin-Alexander Bollmann, Dr. med. *** … Cite this as: Plank PM, Vogel-Claussen
J, Bollmann BA: Necrotizing sarcoid granulomatosis (NSG). …

Risk of post-transplantation diabetes mellitus (PTDM) with different calcineurin inhibitors

BA Bollmann, B Seeliger, J Gottlieb, M Greer - 2016 - Eur Respiratory Soc
Background: Several reports stated that use of tacrolimus (FK) is associated with decreased
glucose tolerance compared to ciclosporin A (CsA). Post-transplantation diabetes mellitus (…